1st Quarter - Report
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC for BOEHRINGER INGELHEIM USA CORPORATION
Firm
Income
—
Expenses
$1,174,158
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Rebates for Dual Eligibles and Low Income Subsidy Populations in Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| ALANNA PORTER TEMME | — |
Pharmacy PHA
Drug Shortages; The Preserving Access to Life Savings Medicines Act (S. 296)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Health Issues HCR
Health Care Reform; Pricing/Rebates; Importation; Coverage; Independent Patient Advisory Board
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Copyright/Patent/Trademark CPT
Patent Settlements; H.R. 1706 (The Protecting Consumer Access to Generic Drugs Act of 2009) and S. 369 (The Preserve Access to Affordable Generics Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY CHEVALIER EFANTIS | — |
| JONATHAN REA MCPHERSON | — |
| PAUL ROMNESS | — |
| ALANNA PORTER TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.